Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy

Ajay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen M. Ansell, Esteban Abella-Dominicis, Brian Koh, Wei Ye, Paul M. Barr, Gilles A. Salles, Jonathan W. Friedberg

Research output: Contribution to journal › Review article › peer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy'. Together they form a unique fingerprint.